First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies.
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Animal embryotoxicity data, and the scarcity of safety data in human pregnancies, have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in lifesaving circumstances. We conducted a meta-analysis of prospective observational studies comparing the risk of miscarriage, stillbirth, and major congenital anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin derivatives versus quinine or no antimalarial treatment. METHODS AND FINDINGS: Electronic databases including Medline, Embase, and Malaria in Pregnancy Library were searched, and investigators contacted. Five studies involving 30,618 pregnancies were included; four from sub-Saharan Africa (n = 6,666 pregnancies, six sites) and one from Thailand (n = 23,952). Antimalarial exposures were ascertained by self-report or active detection and confirmed by prescriptions, clinic cards, and outpatient registers. Cox proportional hazards models, accounting for time under observation and gestational age at enrollment, were used to calculate hazard ratios. Individual participant data (IPD) meta-analysis was used to combine the African studies, and the results were then combined with those from Thailand using aggregated data meta-analysis with a random effects model. There was no difference in the risk of miscarriage associated with the use of artemisinins anytime during the first trimester (n = 37/671) compared with quinine (n = 96/945; adjusted hazard ratio [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%, p = 0.228), in the risk of stillbirth (artemisinins, n = 10/654; quinine, n = 11/615; aHR = 0.29 [95% CI 0.08-1.02], p = 0.053), or in the risk of miscarriage and stillbirth combined (pregnancy loss) (aHR = 0.58 [95% CI 0.36-1.02], p = 0.099). The corresponding risks of miscarriage, stillbirth, and pregnancy loss in a sensitivity analysis restricted to artemisinin exposures during the embryo sensitive period (6-12 wk gestation) were as follows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52-2.04), p = 0.603. The prevalence of major congenital anomalies was similar for first-trimester artemisinin (1.5% [95% CI 0.6%-3.5%]) and quinine exposures (1.2% [95% CI 0.6%-2.4%]). Key limitations of the study include the inability to control for confounding by indication in the African studies, the paucity of data on potential confounders, the limited statistical power to detect differences in congenital anomalies, and the lack of assessment of cardiovascular defects in newborns. CONCLUSIONS: Compared to quinine, artemisinin treatment in the first trimester was not associated with an increased risk of miscarriage or stillbirth. While the data are limited, they indicate no difference in the prevalence of major congenital anomalies between treatment groups. The benefits of 3-d artemisinin combination therapy regimens to treat malaria in early pregnancy are likely to outweigh the adverse outcomes of partially treated malaria, which can occur with oral quinine because of the known poor adherence to 7-d regimens. REVIEW REGISTRATION: PROSPERO CRD42015032371.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The cohort established significant evidence on treatment which informed WHO and changed its global malaria treatment guidelines to artemisinin-based combination therapies (ACTs). 29”
From Cohort Profile: the SMRU Refugee and Migrant Pregnancy Study in Western Thailand and Eastern Myanmar (2026) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ACTS are both more efficacious and safer than previously recommended treatments (like quinine).”
From Cohort Profile: the SMRU Refugee and Migrant Pregnancy Study in Western Thailand and Eastern Myanmar (2026) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701 · cited 1×
“…in four independent prospective observational studies across six sites in sub-Saharan Africa using individual participant data (IPD) meta-analysis [26] and combined the results with summary effect estimates from the Shoklo Malaria Research Unit (SMRU) at the Thailand–Myanmar border, using…”
Epidemiology and burden of malaria in pregnancy
Desai, M., ter Kuile, F. O., Nosten, F., McGready, R., Asamoa, K., Brabin, B., & Newman, R. D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70021-x · Cited by 1,432 · cited 3×
“Consistent with the known adverse effects of malaria in pregnancy [17,18,22,23], our results indicate that pregnancies treated with quinine in early pregnancy were associated with an increased risk of miscarriage compared to pregnancies not requiring treatment for malaria.”
Self-citationThe burden of malaria in pregnancy in malaria-endemic areas
Steketee, R., Nahlen, B., Parise, M., & Menendez, C. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.28 · Cited by 1,063
Self-citationQuinine, an old anti-malarial drug in a modern world: role in the treatment of malaria
Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J., & D'Alessandro, U. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-144 · Cited by 1,007 · cited 2×
“Quinine has been used since the 17th century [40] and is thought to be safe in pregnancy although there have not been any formal studies in early pregnancy assessing its safety and efficacy [44].”
Self-citationAn analysis of malaria in pregnancy in Africa.
Brabin, B. J. (1983) · PubMed · Cited by 782
Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study
Dellicour, S., Tatem, A. J., Guerra, C. A., Snow, R. W., & ter Kuile, F. O. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000221 · Cited by 490 · cited 1×
“Despite the high burden of malaria in pregnancy, with an estimated 125 million at risk of infection annually in malaria endemic regions globally [49], fewer than 1,700 episodes of firstMeta-analysis of the safety of artemisinin and quinine in first trimester”
Self-citationClinical Epidemiology: How to Do Clinical Practice Research
Heneghan, C. (2006) · ACP Journal Club · doi:10.7326/acpjc-2006-145-1-a11 · Cited by 403
Clinical Epidemiology: How to Do Clinical Practice Research
Haynes, R. B., Sackett, D. L., Guyatt, G. H., & Tugwell, P. (2005) · Medical Entomology and Zoology · Cited by 361
The epidemiology of severe malaria in an area of low transmission in Thailand.
Luxemburger, C., Ricci, F., Nosten, F., Raimond, D., Bathet, S., & White, N. J. (1997) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(97)90066-3 · Cited by 299
Self-citationGuyatt, H., & Snow, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.36 · Cited by 252 · cited 2×
“Consistent with the known adverse effects of malaria in pregnancy [17,18,22,23], our results indicate that pregnancies treated with quinine in early pregnancy were associated with an increased risk of miscarriage compared to pregnancies not requiring treatment for malaria.”
McGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228 · cited 10×
“The sensitivity analysis examining the effect of removing one study site at a time on the overall aggregated effect estimates showed that the effect estimates were stable, with minimal variation due to exclusion of individual sites (aHRs for first-trimester ACT versus quinine ranged from 0.51 when Thailand data were o…”
InfluentialSelf-citationArtesunate versus quinine for treating severe malaria
Sinclair, D., Donegan, S., Isba, R., & Lalloo, D. G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005967.pub4 · Cited by 224 · cited 1×
“Trials in Southeast Asia, South America, and Africa found that artemisinins performed better than quinine for the treatment of severe malaria [43], uncomplicated malaria in non-pregnant adults [40], and malaria in the second and third trimester of pregnancy [19].”
Antimalarial Drugs in Pregnancy: A Review
Nosten, F., McGready, R., d'Alessandro, U., Bonell, A., Verhoeff, F., Menendez, C., Mutabingwa, T., & Brabin, B. (2006) · Current Drug Safety · doi:10.2174/157488606775252584 · Cited by 164 · cited 1×
“Quinine has been used since the 17th century [40] and is thought to be safe in pregnancy although there have not been any formal studies in early pregnancy assessing its safety and efficacy [44].”
Self-citationTHE CONTRIBUTION OF MALARIA IN PREGNANCY TO PERINATAL MORTALITY
VAN GEERTRUYDEN, J.-P., THOMAS, F., ERHART, A., & D’ALESSANDRO, U. (2004) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.71.35 · Cited by 161
Self-citationDevelopmental toxicity of artesunate and an artesunate combination in the rat and rabbit
Clark, R. L., White, T. E. K., A. Clode, S., Gaunt, I., Winstanley, P., & Ward, S. A. (2004) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20027 · Cited by 142 · cited 1×
“In rodents, artemisinins cause embryolethality as well as cardiovascular (ventricular septal and vessel defects) and skeletal defects (shortened or bent long bones and scapulae, misshapen ribs, cleft sternebrae, and incompletely ossified pelvic bones) [6].”
Clark, R. L. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.05.002 · Cited by 124 · cited 2×
“It is unknown how findings from animal studies would translate in humans because the mechanism of teratogenicity and the drug sensitive period may differ significantly in humans [3,12].”
Conditions for Bias from Differential Left Truncation
Howards, P. P., Hertz‐Picciotto, I., & Poole, C. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwk027 · Cited by 121 · cited 1×
“A strength of this meta-analysis is the ability to standardize analyses across studies, including definitions of the embryo sensitive period, definitions of what constituted a confirmed treatment, and use of left truncation in the survival analysis for miscarriage [47] to avoid bias when gestational age at exposure an…”
Brian Haynes, R. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.006 · Cited by 117 · cited 11×
“Further details on statistical methods are provided in S4 Text.”
InfluentialArtesunate versus quinine for treating severe malaria
Sinclair, D., Donegan, S., & Lalloo, D. G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005967.pub3 · Cited by 111
Moore, K. A., Simpson, J. A., Paw, M. K., Pimanpanarak, M., Wiladphaingern, J., Rijken, M. J., Jittamala, P., White, N. J., Fowkes, F. J. I., Nosten, F., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00547-2 · Cited by 84
Self-citationLongo, M., Zanoncelli, S., Torre, P. D., Riflettuto, M., Cocco, F., Pesenti, M., Giusti, A. M., Colombo, P., Brughera, M., Mazué, G., et al. (2006) · Reproductive Toxicology · doi:10.1016/j.reprotox.2006.08.001 · Cited by 82
Obonyo, C., & Juma, E. A. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-2 · Cited by 70 · cited 1×
“Though WHO recommends the combination of quinine and clindamycin, this combination is rarely used in practice due to high cost [45] and the low availability of clindamycin in malaria endemic countries.”
Artesunate: developmental toxicity and toxicokinetics in monkeys
Clark, R. L., Arima, A., Makori, N., Nakata, Y., Bernard, F., Gristwood, W., Harrell, A., White, T. E. K., & Wier, P. J. (2008) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20163 · Cited by 68 · cited 1×
“In monkeys, embryolethality was observed following prolonged treatment (12 to 20 d), but there were no malformations [2,4].”
InfluentialManyando, C., Mkandawire, R., Puma, L., Sinkala, M., Mpabalwani, E., Njunju, E., Gomes, M., Ribeiro, I., Walter, V., Virtanen, M., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-249 · Cited by 67
Self-citationBurden of Malaria in Early Pregnancy: A Neglected Problem?
Huynh, B.-T., Cottrell, G., Cot, M., & Briand, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu848 · Cited by 63
Clark, R. L., Lerman, S. A., Cox, E. M., Gristwood, W. E., & White, T. E. K. (2008) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20165 · Cited by 60
Scheuerle, A. E., & Tilson, H. H. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.726 · Cited by 59
Sensitive periods for developmental toxicity of orally administered artesunate in the rat
White, T. E. K., & Clark, R. L. (2008) · Birth Defects Research Part B: Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20157 · Cited by 57
Poespoprodjo, J. R., Fobia, W., Kenangalem, E., Lampah, D. A., Sugiarto, P., Tjitra, E., Anstey, N. M., & Price, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084976 · Cited by 51
Dellicour, S., ter Kuile, F. O., & Stergachis, A. S. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050187 · Cited by 49
Self-citationLi, Q., & Weina, P. J. (2009) · Molecules · doi:10.3390/molecules15010040 · Cited by 43 · cited 2×
“Animal reproductive toxicity studies suggest that the embryo sensitive period in humans for artemisinins is between 4 and 10 wk post-conception (6–12 wk after last menstrual period) [11,12].”
Hill, J., D'Mello-Guyett, L., Hoyt, J., van Eijk, A. M., ter Kuile, F. O., & Webster, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001688 · Cited by 42
Holmes, L. B., & Westgate, M. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20842 · Cited by 41 · cited 1×
“For the other studies, criteria to differentiate between major and minor anomalies and to determine anomalies for exclusion, such as genetic and chromosomal disorders, were applied based on the WHO Birth Defect Panel recommendations and published criteria [32].”
Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort
Mosha, D., Mazuguni, F., Mrema, S., Sevene, E., Abdulla, S., & Genton, B. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-197 · Cited by 38
Self-citationClark, R. L. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.22868 · Cited by 35 · cited 3×
“Information on malaria confirmation is important as malaria-infected cells could be at less risk of artemisinin toxicity [11].”
Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings
Mehta, U., Clerk, C., Allen, E. N., Yore, M. A., Sevene, E., Singlovic, J., Petzold, M., Mangiaterra, V., Elefant, E., Sullivan, F. M., et al. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-89 · Cited by 34
Self-citationBurger, R. J., van Eijk, A. M., Bussink, M., Hill, J., & ter Kuile, F. O. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv170 · Cited by 33 · cited 6×
“• Animal embryotoxicity data and the paucity of safety data in human pregnancies have prevented artemisinin derivatives from being recommended for malaria treatment in the first trimester except in life-saving circumstances, yet in malaria endemic countries, many early pregnancies are advertently or inadvertently expo…”
InfluentialPatterns of anti-malarial drug treatment among pregnant women in Uganda
Sangaré, L. R., Weiss, N. S., Brentlinger, P. E., Richardson, B. A., Staedke, S. G., Kiwuwa, M. S., & Stergachis, A. S. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-152 · Cited by 32
Self-citationPharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
Rulisa, S., Kaligirwa, N., Agaba, S., Karema, C., Mens, P. F., & de Vries, P. J. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-225 · Cited by 29
Self-citationDellicour, S., Desai, M., Aol, G., Oneko, M., Ouma, P., Bigogo, G., Burton, D. C., Breiman, R. F., Hamel, M. J., Slutsker, L., et al. (2015) · Malaria Journal · doi:10.1186/s12936-015-0950-6 · Cited by 28
Self-citationTinto, H., Sevene, E., Dellicour, S., Calip, G. S., D’Alessandro, U., Macete, E., Diallo, S. N., Kazienga, A., Valéa, I., Sorgho, H., et al. (2015) · Reproductive Health · doi:10.1186/s12978-015-0101-0 · Cited by 28
Self-citationKioko, U., Riley, C., Dellicour, S., Were, V. O., Ouma, P., Gutman, J., Kariuki, S., Omar, A. H., Desai, M. R., & Buff, A. M. (2016) · Malaria Journal · doi:10.1186/s12936-016-1404-5 · Cited by 24
Self-citationEffects of gestational age at enrollment in pregnancy exposure registries
Margulis, A. V., Mittleman, M. A., Glynn, R. J., Holmes, L. B., & Hernández–Díaz, S. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3731 · Cited by 23 · cited 1×
“A strength of this meta-analysis is the ability to standardize analyses across studies, including definitions of the embryo sensitive period, definitions of what constituted a confirmed treatment, and use of left truncation in the survival analysis for miscarriage [47] to avoid bias when gestational age at exposure an…”
Evaluation of the developmental toxicity of artemether during different phases of rat pregnancy
El‐Dakdoky, M. H. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.03.027 · Cited by 20
McGready, R., Kang, J., Watts, I., Tyrosvoutis, M. E. G., Torchinsky, M. B., Htut, A. M., Tun, N. W., Keereecharoen, L., Wangsing, C., Hanboonkunupakarn, B., et al. (2015) · F1000Research · doi:10.12688/f1000research.4190.2 · Cited by 19
Self-citationMcGready, R. M., Kang, J., Watts, I. V. C., Tyrosvoutis, M. E. G., Torchinsky, M. B., Htut, A. M., Tun, N. W., Keereecharoen, L., Wangsing, C., Hanboonkunupakarn, B., et al. (2014) · F1000Research · doi:10.12688/f1000research.4190.1 · Cited by 11
Self-citationSome Pregnancy-Related Effects of Artemether in Laboratory Animals
Ejiofor, J. I., Kwanashie, H. O., & Anuka, J. A. (2006) · Pharmacology · doi:10.1159/000094521 · Cited by 11
Research works printed but not linked: 1
- R Clark, 2006, Artesunate: developmental toxicity in monkeys, Birth Defects Res A Clin Mol Teratol, 76, 329
Cited by
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
“Of Oxford, UK) NMRC-M3V-Ad-Pf5 (NMRC) GMZ2 (EVI*, UKT, SSI, ASH, AMANET, NHRC, CNRFP, LSHTM, MUK and MRCG) MSP3 [181-276] (AMANET, EVI, CHUV, Bamako U.”
Self-citationAshley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Varo, R., Chaccour, C., & Bassat, Q. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.05.010 · Cited by 174
“41 Congenital malaria is rare in endemic countries where mothers have high level of antibodies which they transmit to their offspring, however this complication needs to be taken into consideration when naïve pregnant women with no immunity whatsoever against malaria travel to endemic areas and get…”
Plewes, K., Leopold, S. J., Kingston, H. W. F., & Dondorp, A. M. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2018.10.002 · Cited by 153
Saito, M., Briand, V., Min, A. M., & McGready, R. (2020) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30099-7 · Cited by 61
Self-citation
Metadata
- Authors
- Dellicour, S., Sevene, E., McGready, R., Tinto, H., Mosha, D., Manyando, C., Rulisa, S., Desai, M., Ouma, P., Oneko, M., Vala, A., Rupérez, M., Macete, E., Menéndez, C., Nakanabo-Diallo, S., Kazienga, A., Valéa, I., Calip, G., Augusto, O., Genton, B., Njunju, E. M., Moore, K. A., d’Alessandro, U., Nosten, F., ter Kuile, F., & Stergachis, A.
- Affiliations
- University of Liverpool (GB)
- Eduardo Mondlane University (MZ)
- Mahidol University (TH)
- Centre Muraz (BF)
- Ifakara Health Institute (TZ)
- Tropical Diseases Research Centre (ZM)
- University of Rwanda (RW)
- Centers for Disease Control and Prevention (US)
- Kenya Medical Research Institute (KE)
- Manhiça Health Research Centre (MZ)
- University of Illinois Chicago (US)
- Swiss Tropical and Public Health Institute (CH)
- Copperbelt University (ZM)
- Burnet Institute (AU)
- London School of Hygiene & Tropical Medicine (GB)
- University of Washington (US)
- Corresponding author
- Dellicour, Stephanie
- Stergachis, Andy
- ORCID
- Dellicour, Stephanie
- Sevene, Esperança
- McGready, Rose
- Tinto, Halidou
- Mosha, Dominic
- Manyando, Christine
- Rulisa, Stephen
- Desai, Meghna
- Oneko, Martina
- Macete, Eusébio
- Menéndez, Clara
- Nakanabo-Diallo, Seydou
- Kazienga, Adama
- Valéa, Innocent
- Calip, Gregory
- Augusto, Orvalho
- Genton, Blaise
- Moore, Kerryn A.
- d’Alessandro, Umberto
- Nosten, Francois
- Stergachis, Andy
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-02
- Volume
- 14
- Issue
- 5
- Pages
- e1002290
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5412992
- OpenAlex
- W2610284326
- Semantic Scholar
- 92e4596686fa9355db40b83f936b6ca0383e4ca0
- Cited by
- 90
- References
- 49
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 1 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 29 · 2019: 9 · 2018: 9 · 2017: 5
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- IHI Repository (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- IRIS (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- edoc (University of Basel) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Bill and Melinda Gates Foundation (Malaria in Pregnancy Consortium)
- Wellcome Trust (Shoklo Malaria Research Unit)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- artemisinin derivatives, quinine, malaria in pregnancy, first trimester, miscarriage, stillbirth, major congenital malformations, antimalarial drug safety, sub-Saharan Africa, Thailand, drug safety in pregnancy
- MeSH terms
- Abnormalities, Drug-Induced, Abortion, Spontaneous, Asia, Southeastern, Female, Humans, Pregnancy, Pregnancy Trimester, First, Quinine, Prevalence, Africa South of the Sahara, Risk Assessment, Artemisinins, Stillbirth, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.